Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)

Colon Cancer Clinical Trial

— GECOP-MMC  

Official title:

Phase IV Multicentric Clinical Trial to Evaluate the Efficacy of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Mytomicin-C After Complete Surgical Cytoreduction in Patients With Colon Cancer Peritoneal Metastases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05250648
• Other study ID #: GECOP-MMC
• Secondary ID: 2019-004679-37
• Status: Recruiting
• Phase: Phase 4
• Start date: March 2, 2022
• Est. completion date: January 2027

Study information

• Verified date: September 2023
• Source: Hospital Universitario de Fuenlabrada
• Contact: Fernando Pereira, PhD
• Phone: +34916006455
• Email: fernando.pereira[@]salud.madrid.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this study is to assess whether there are differences in PERITONEAL RECURRENCE in patients with Colon Cancer Peritoneal Metastases treated with complete surgical resection and systemic chemotherapy, with (Group 1) or without (Group 2) HIPEC with Mitomycin-C.

Description:

CytoReductive Surgery (CRS) + Hyperthermic IntraPEritoneal Chemotherapy (HIPEC), especially from the year 2000 onwards, has obtained unprecedented results in patients with low to moderate volume peritoneal metastases (PM) of colorectal cancer (CRC), so that it has gradually been accepted, even being considered the best treatment for these patients. However, the actual role of HIPEC as a necessary component of treatment is unknown, despite its proven experimental basis. The French PRODIGE 7 study, presented at ASCO in 2018 and published on January 2021, has raised doubts about the survival benefit of HIPEC. In this study, there was no difference in overall survival (OS) with or without HIPEC (with Oxaliplatin 30 minutes) after resection of PM-CRC. However, since its presentation, several methodological flaws have been identified: a short exposure time to Oxaliplatin, an overestimation of the effect of HIPEC on OS (18 months) considered for the sample calculation, or the choice of OS as the main endpoint (since HIPEC can reduce peritoneal relapses, while OS is also influenced by the systemic treatment received by all patients). Due to these shortcomings and some others, the results have not been assumed to be definitive. Therefore, the majority of units specialized in peritoneal surface malignancy, continue to consider HIPEC in these patients as a recommended option, usually changing Oxaliplatin for Mitomycin-C (MMC). With these premises we propose this multicenter Clinical Trial, correcting the retrospective defects of PRODIGE 7. To do this, the cytostatic used in HIPEC will be changed (MMC instead of oxaliplatin), the infusion time will be increased (from 30 to 90 minutes), rectal cancers are ruled out (only colon cancers will be included), cases with high peritoneal extension (PCI> 20) will be avoided, those cases in which a complete CRS (CCS 0) is not achieved will be excluded, and the main objective will be the Peritoneal Recurrence Free Survival (RFS) instead of the OS.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 216
• Est. completion date: January 2027
• Est. primary completion date: January 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically confirmed colon adenocarcinoma, except signet ring cell carcinomas (those with > 50% of the tumor composed of these cells, which comprise only 1% of all colon adenocarcinomas).

2. Absence of previously treated or current extraperitoneal metastases, including distant lymphadenopathy (retroperitoneal, mediastinal, etc), liver metastases, or lung metastases (ruled out by PET-scan in case of doubt).

3. Synchronous or metachronous peritoneal metastasis of mild to moderate volume, with a PCI = 20 (Appendix 2) (intraoperative confirmation).

4. Macroscopically complete surgical cytoreduction CCS-0 (intraoperative confirmation).

5. Treatment with perioperative systemic chemotherapy (SCT), before and/or after surgical procedure.

6. Age> 18 years.

7. Acceptable anesthetic/surgical risk: ASA 1-3 (Appendix 3), ECOG 0-1 (Appendix 4). No severe alterations in hematological, renal, cardiac, pulmonary or hepatic function (operable patients).

8. Information to the patient and signing of a study-specific informed consent.

Exclusion Criteria:

1. Peritoneal carcinomatosis of any other origin, particularly rectal cancer or appendicular adenocarcinoma, or signet ring cell colon cancer on histology.

2. No intraoperative confirmation of peritoneal disease (PCI 0). Likewise, cases of perianastomotic (local) or lymph node (locoregional) recurrences will be excluded.

3. High volume peritoneal disease with a PCI> 20 (intraoperative evaluation).

4. Concurrent or previously treated extraperitoneal disease.

5. Disease progression during preoperative chemotherapy, if received.

6. Patients previously treated with HIPEC.

7. History of other cancers (except cutaneous basal cell carcinoma or cervix carcinoma in situ) in the 5 years prior to entry into the study.

8. Patients included in another first-line clinical trial for the studied disease.

9. Pregnancy (or suspicion of it) or lactation period.

10. Emergency surgical intervention for obstruction or perforation of a primary tumour with synchronous PM (although rescue and secondary CRS + HIPEC after emergency surgery of the primary tumour are acceptable if inclusion criteria are fulfilled).

11. Persons deprived of liberty or under legal or administrative supervision.

12. Inability to understand the nature of the intervention, the risks, benefits, expected evolution and the need to undergo periodic medical examinations, either for geographical, social or psychological reasons.

Related Conditions & MeSH terms

• Carcinoma
• Colon Cancer
• Colonic Neoplasms
• Neoplasm Metastasis
• Peritoneal Carcinomatosis
• Peritoneal Neoplasms

Intervention

Drug:
• complete cytoreductive surgery plus HIPEC with Mytomicin C for 90 minutes
In the arm with HIPEC, this will be performed with Mytomicin C, at a dose of 35 mg/m2 in peritoneal dialysis solution (2 liter/m2) for 90 minutes, with dose fractionation: 50% min 0, 25% min 30, 25% min 60

Procedure:
• complete cytoreductive surgery without HIPEC
in the arm without HIPEC, only complete cytoreductive surgery will be performed

Locations

Country	Name	City	State
Spain	Hospital Universitario Principe de Asturias	Alcalá de Henares	Madrid
Spain	Hospital Universitario Fundación Alcorcón	Alcorcón	Madrid
Spain	Hospital Universitario Torrecárdenas	Almería
Spain	Complejo Hospitalario Universitario de Badajoz	Badajoz
Spain	Hospital General Universitario de Castellón	Castelló de la Plana	Castellón
Spain	Consorcio Hospitalario Provincial de Castellón	Castellón De La Plana	Castellón
Spain	Hospital General Universitario de Ciudad Real	Ciudad Real
Spain	Hospital Universitario Reina Sofía	Córdoba
Spain	Hospital Universitario Virgen de La Arrixaca	El Palmar	Murcia
Spain	Hospital General Universitario de Elche	Elche	Alicante
Spain	HOSPITAL UNIVERSITARIO DE FUENLABRADA (Coordinating Centre)	Fuenlabrada	Madrid
Spain	Hospital Universitario de Gran Canaria Doctor Negrín	Las Palmas De Gran Canaria	Gran Canaria
Spain	Fundación Jiménez Díaz	Madrid
Spain	Hospital General Universitario Gregorio Marañón	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramón Y Cajal	Madrid
Spain	Md Anderson Cancer Center	Madrid
Spain	Hospital Quirónsalud Málaga	Málaga
Spain	Hospital General Universitario Reina Sofía	Murcia
Spain	Hospital Universitario Central de Asturias	Oviedo	Asturias
Spain	Hospital Universitario Son Espases	Palma De Mallorca	Mallorca
Spain	Hospital Universitario Donostia	San Sebastián	Gipuzkoa
Spain	Hospital Sant Joan Despi Moises Broggi	Sant Joan Despí	Barcelona
Spain	Hospital Universitario Virgen Del Rocío	Sevilla
Spain	Hospital Universitario Infanta Elena	Valdemoro	Madrid
Spain	Hospital Clinico Universitario de Valencia	Valencia
Spain	Hospital Universitario Y Politécnico La Fe	Valencia
Spain	Instituto Valenciano de Oncología	Valencia
Spain	Hospital Universitario Río Hortega	Valladolid
Spain	Hospital Clínico Universitario "Lozano Blesa"	Zaragoza

Sponsors (2)

Lead Sponsor	Collaborator
Hospital Universitario de Fuenlabrada	Instituto de Investigación Hospital Universitario La Paz

Country where clinical trial is conducted

Spain, 

References & Publications (1)

Pereira F, Serrano A, Manzanedo I, Perez-Viejo E, Gonzalez-Moreno S, Gonzalez-Bayon L, Arjona-Sanchez A, Torres J, Ramos I, Barrios ME, Cascales P, Morales R, Boldo E, Garcia-Fadrique A, Arteaga X, Gutierrez-Calvo A, Sanchez-Garcia S, Asensio E, Ramirez C — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Peritoneal Recurrence Free Survival	From the date of surgery to the date of peritoneal recurrence or death, or to the end of follow-up	3 years
Secondary	Global recurrence at any location (Disease Free Survival)	From the date of surgery to the date of recurrence at any site or death	3 years
Secondary	Locoregional and distant recurrence rate (isolated or coincident, with or without simultaneous peritoneal recurrence)	From the date of surgery to the date of locoregional and/or distant recurrence	3 years
Secondary	Postoperative complications (rate and severity grade)	Using the CTCAE v5.0 adverse event classification system, including those related to HIPEC.	days 1-90 after surgery
Secondary	Peritoneal and global recurrence rate according to stratified PCI	Rate of peritoneal and global recurrence in 3 subgroups of PCI ((1-10, 11-15, 16-20)	3 years
Secondary	Overall survival	Months from from the day of treatment initiation (either neoadjuvant SCT or upfront CRS) to the date of death or to the end of follow-up.	3 years
Secondary	Quality of Life with EORTC validated questionnaire Core 30 (QLQ-C30)	The QLQ-CR29 is a supplementary questionnaire module to be employed in conjunction with the QLQ-C30. In fact, their numbering is consecutive (the last item of QLQ-C30 is number 30, being the first item of QLQ-CR29 number 31). Both have function and symptom scales/single-items. All of the scales and single-item measures range in score from 0 to 100. A high score for the functional scale and functional single-items represents a high level of functioning, whereas a high score for the symptom scales and symptom single-items represents a high level of symptomatology or problems.	pre-surgery, at the end of postoperative SCT (an average 4-6 months), at 12 months and at 24 months
Secondary	Quality of Life with EORTC validated questionnaire Colorectal Cancer Module (QLQ-CR29).	The QLQ-CR29 is a supplementary questionnaire module to be employed in conjunction with the QLQ-C30. In fact, their numbering is consecutive (the last item of QLQ-C30 is number 30, being the first item of QLQ-CR29 number 31). Both have function and symptom scales/single-items. All of the scales and single-item measures range in score from 0 to 100. A high score for the functional scale and functional single-items represents a high level of functioning, whereas a high score for the symptom scales and symptom single-items represents a high level of symptomatology or problems.	pre-surgery, at the end of postoperative SCT (an average 4-6 months), at 12 months and at 24 months